Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

Stanford University

Status: Completed

Conditions: Blood and Marrow Transplant (BMT); Myeloproliferative Disorders; Myelodysplastic Syndromes (MDS); Myelodysplastic Syndromes; Myeloproliferative Disorders (MPD)

Treatments: Procedure: nonmyeloablative allogeneic hematopoietic cell transplant

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00186576

NCT00186576

BMT128

75826

Details and patient eligibility

About

To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.

Full description

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- Myelodysplastic Syndromes

• Myeloproliferative Disorders
• HLA matched donor available Exclusion Criteria:- organ dysfunction
• HIV positive

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)